Pentraxin-3 could be a useful biomarker in monitoring disease activity in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, according to investigators.

Plasma and urinary levels of the protein appear to reflect disease activity in ANCA-associated vasculitis better than C-reactive protein (CRP), especially in patients with kidney involvement, Asta D. Jonasdottir, MD, of The National University Hospital of Iceland in Reykjavik, and colleagues reported in the Scandinavian Journal of Rheumatology. Pentraxin-3 is widely produced by a variety of cells whereas CRP is produced mainly in the liver.

The investigators measured plasma levels of pentraxin-3 in 79 patients with newly diagnosed or relapsing ANCA-associated vasculitis at baseline and at a 6-month follow-up visit and in 23 healthy patients serving as a control group. They also measured urinary pentraxin-3 in 34 of the patients. Dr Jonasdottir’s team also measured CRP, creatinine, and albuminuria levels.

Continue Reading

Plasma pentraxin-3 levels in the patients were significantly higher at baseline than at 6 months (2.85 vs 1.23 ng/mL). The levels also were significantly higher at baseline and at 6 months in patients compared with the control group. Plasma and urinary pentraxin-3 levels correlated with Birmingham Vasculitis Activity Score (BVAS) at baseline. The investigators observed a significant correlation between both plasma and urinary pentraxin-3 levels and estimated glomerular filtration rate and albuminuria. They observed no correlation between plasma and urinary pentraxin-3 levels.

In addition, plasma and urinary pentraxin-3 levels at baseline were significantly higher in patients with kidney involvement. The investigators found no correlation at baseline between pentraxin-3 levels and CRP and between CRP and BVAS.


Jonasdottir AD, Antovic A, Qureshi AR, et al. Pentraxin-3 — a potential biomarker in ANCA-associated vasculitis. Scand J Rheumatol. 2023;52(3):293-301 doi:10.1080/03009742.2022.2045790